{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T15:31:27Z","timestamp":1762875087149},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2007,3,1]],"date-time":"2007-03-01T00:00:00Z","timestamp":1172707200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/2.0"},{"start":{"date-parts":[[2007,3,31]],"date-time":"2007-03-31T00:00:00Z","timestamp":1175299200000},"content-version":"vor","delay-in-days":30,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/2.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Emergency Med"],"published-print":{"date-parts":[[2007,3]]},"DOI":"10.1007\/s11739-007-0003-4","type":"journal-article","created":{"date-parts":[[2007,4,15]],"date-time":"2007-04-15T15:51:43Z","timestamp":1176652303000},"page":"13-18","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["The treatment of polycythaemia vera: an update in the JAK2 era"],"prefix":"10.1007","volume":"2","author":[{"given":"G.","family":"Finazzi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Barbui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2007,3,31]]},"reference":[{"key":"3_CR1","doi-asserted-by":"publisher","first-page":"4214","DOI":"10.1182\/blood-2005-08-3526","volume":"107","author":"A.I. Schafer","year":"2006","unstructured":"Schafer AI (2006) Molecular basis of the diagnosis and treatment of polycythemia vera and essential thrombocythemia. Blood 107:4214\u20134222","journal-title":"Blood"},{"key":"3_CR2","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.blre.2005.01.001","volume":"19","author":"G. Finazzi","year":"2005","unstructured":"Finazzi G, Barbui T (2005) Risk-adapted therapy in essential thrombocythemia and polycythemia vera. Blood Rev 19:243\u2013252","journal-title":"Blood Rev"},{"key":"3_CR3","first-page":"132","volume":"23","author":"P.D. Berk","year":"1986","unstructured":"Berk PD, Goldberg JD, Donovan PB et al (1986) Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols. Semin Hematol 23:132\u2013143","journal-title":"Semin Hematol"},{"key":"3_CR4","first-page":"17","volume":"34","author":"S.M. Fruchtman","year":"1997","unstructured":"Fruchtman SM, Mack K, Kaplan ME et al (1997) From efficacy to safety: a polycythemia vera study group report on hydroxyurea in patients with polycythemia vera. Semin Hematol 34:17","journal-title":"Semin Hematol"},{"key":"3_CR5","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1200\/JCO.2005.07.062","volume":"23","author":"R. Marchioli","year":"2005","unstructured":"Marchioli R, Finazzi G, Landolfi R et al (2005) Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol 23:2224\u20132232","journal-title":"J Clin Oncol"},{"key":"3_CR6","first-page":"172","volume":"23","author":"A.P. Tartaglia","year":"1986","unstructured":"Tartaglia AP, Goldberg JD, Berk PD et al (1986) Adverse effects of antiaggregating platelet therapy in the treatment of polycythemia vera. Semin Hematol 23:172\u2013176","journal-title":"Semin Hematol"},{"key":"3_CR7","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1182\/blood.V99.4.1144","volume":"99","author":"M.B. Streiff","year":"2002","unstructured":"Streiff MB, Smith B, Spivak JL (2002) The diagnosis and management of polycythemia vera in the era since the Polycythemia Vera Study Group: a survey of the American Society of Hematology members\u2019 practice patterns. Blood 99:1144\u20131149","journal-title":"Blood"},{"key":"3_CR8","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1056\/NEJMoa035572","volume":"350","author":"R. Landolfi","year":"2004","unstructured":"Landolfi R, Marchioli R, Kutti J et al (2004) Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med 350:114\u2013124","journal-title":"N Engl J Med"},{"key":"3_CR9","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1046\/j.1365-2141.1999.01224.x","volume":"104","author":"P.J.J. Van Genderen","year":"1999","unstructured":"Van Genderen PJJ, Prins F, Michiels JJ et al (1999) Thromboxane-dependent platelet activation in vivo precedes arterial thrombosis in thrombocythaemia: a rationale for the use of low-dose aspirin as an antithrombotic agent. Br J Haematol 104:438\u2013441","journal-title":"Br J Haematol"},{"key":"3_CR10","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1016\/S0140-6736(78)92098-6","volume":"2","author":"T.C. Pearson","year":"1978","unstructured":"Pearson TC, Wetherley-Mein G (1978) Vascular occlusive episodes and venous haematocrit in primary proliferative polycythaemia. Lancet 2:1219\u20131222","journal-title":"Lancet"},{"key":"3_CR11","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1056\/NEJMra052717","volume":"353","author":"C. Patrono","year":"2005","unstructured":"Patrono C, Garcia-Rodriguez LA, Landolfi R et al (2005) Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 353:2373\u20132383","journal-title":"N Engl J Med"},{"key":"3_CR12","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1002\/(SICI)1096-8652(199605)52:1<42::AID-AJH7>3.0.CO;2-6","volume":"52","author":"S. Nand","year":"1996","unstructured":"Nand S, Stock W, Godwin J et al (1996) Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia and myeloid metaplasia with myelofibrosis. Am J Hematol 52:42\u201346","journal-title":"Am J Hematol"},{"key":"3_CR13","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1182\/blood.V91.2.616","volume":"91","author":"Y. Sterkers","year":"1998","unstructured":"Sterkers Y, Preudhomme C, Lai J-L et al (1998) Acute myeloid leukemia and myelodyslastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion. Blood 91:616\u2013622","journal-title":"Blood"},{"key":"3_CR14","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.1182\/blood.V95.11.3589","volume":"95","author":"V.N. Hanft","year":"2000","unstructured":"Hanft VN, Fruchtman SR, Pickens CV et al (2000) Acquired DNA mutations associated with in vivo hydroxyurea exposure. Blood 95:3589\u20133593","journal-title":"Blood"},{"key":"3_CR15","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1053\/j.seminhematol.2005.05.021","volume":"42","author":"R. Marchioli","year":"2005","unstructured":"Marchioli R, Finazzi G, Marfisi RM et al (2005) Clinical trials in myeloproliferative disorders: looking forward. Semin Hematol 42:259\u2013265","journal-title":"Semin Hematol"},{"key":"3_CR16","doi-asserted-by":"publisher","first-page":"2664","DOI":"10.1182\/blood-2004-09-3426","volume":"105","author":"G. Finazzi","year":"2005","unstructured":"Finazzi G, Caruso V, Marchioli R et al (2005) Acute leukemia in polycythemia vera. An analysis of 1,638 patients enrolled in a prospective observational study. Blood 105:2664\u20132670","journal-title":"Blood"},{"key":"3_CR17","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1046\/j.1365-2141.2000.02188.x","volume":"110","author":"G. Finazzi","year":"2000","unstructured":"Finazzi G, Ruggeri M, Rodeghiero F et al (2000) Second malignancies in patients with essential thrombocythemia treated with busulphan and hydroxyurea: long-term followup of a randomized clinical trial. Br J Haematol 110:577\u2013583","journal-title":"Br J Haematol"},{"key":"3_CR18","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.7326\/0003-4819-119-11-199312010-00006","volume":"119","author":"R.T. Silver","year":"1993","unstructured":"Silver RT (1993) Interferon alpha2b: a new treatment for polycythemia vera. Ann Intern Med 119:1091\u20131092","journal-title":"Ann Intern Med"},{"key":"3_CR19","first-page":"257","volume":"2","author":"M.C. Martyre","year":"2003","unstructured":"Martyre MC (2003) Critical review of pathogenetic mechanisms in myelofibrosis with myeloid metaplasia. Curr Hematol Rep 2:257\u2013263","journal-title":"Curr Hematol Rep"},{"key":"3_CR20","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s002770050563","volume":"79","author":"E. Lengfelder","year":"2000","unstructured":"Lengfelder E, Berger U, Hehlmann R (2000) Interferon alpha in the treatment of polycythemia vera. Ann Hematol 79:103\u2013109","journal-title":"Ann Hematol"},{"key":"3_CR21","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/j.1600-0609.1999.tb01110.x","volume":"62","author":"N. Heis","year":"1999","unstructured":"Heis N, Rintelen C, Gisslinger B et al (1999) The effect of interferon alpha on myeloproliferation and vascular complications in polycythemia vera. Eur J Haematol 62:27\u201331","journal-title":"Eur J Haematol"},{"key":"3_CR22","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1002\/(SICI)1097-0142(19980915)83:6<1205::AID-CNCR21>3.0.CO;2-8","volume":"83","author":"H.S. Gilbert","year":"1998","unstructured":"Gilbert HS (1998) Long term treatment of myeloproliferative disease with interferon alpha-2b: feasibility and efficacy. Cancer 83:1205\u20131213","journal-title":"Cancer"},{"key":"3_CR23","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1002\/cncr.22026","volume":"107","author":"R.T. Silver","year":"2006","unstructured":"Silver RT (2006) Long-term effects of the treatment of polycythemia vera with recombinant interferon-alpha. Cancer 107:451\u2013458","journal-title":"Cancer"},{"key":"3_CR24","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1038\/nature03546","volume":"434","author":"C. James","year":"2005","unstructured":"James C, Ugo V, Le Couedic JP et al (2005) A unique clonal JAK2 mutation leading to constitutive signaling causes polycythemia vera. Nature 434:1144\u20131148","journal-title":"Nature"},{"key":"3_CR25","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","volume":"7","author":"R.L. Levine","year":"2005","unstructured":"Levine RL, Wadleigh M, Cools J et al (2005) Activating mutation of the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7:387\u2013397","journal-title":"Cancer Cell"},{"key":"3_CR26","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","volume":"365","author":"E.J. Baxter","year":"2005","unstructured":"Baxter EJ, Scott LM, Campbell PJ et al (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative diseases. Lancet 365:1054\u20131061","journal-title":"Lancet"},{"key":"3_CR27","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1056\/NEJMoa051113","volume":"352","author":"R. Kralovics","year":"2005","unstructured":"Kralovics R, Passamonti F, Buser AS et al (2005) A gain-offunction mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352:1779\u20131790","journal-title":"N Engl J Med"},{"key":"3_CR28","doi-asserted-by":"publisher","first-page":"22788","DOI":"10.1074\/jbc.C500138200","volume":"280","author":"R. Zhao","year":"2005","unstructured":"Zhao R, Xing S, Li Z et al (2005) Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem 280:22788\u201322792","journal-title":"J Biol Chem"},{"key":"3_CR29","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1182\/blood-2005-03-1320","volume":"106","author":"A.V. Jones","year":"2005","unstructured":"Jones AV, Kreil S, Zoi K et al (2005) Widespread occurrence of the JAK2 V617 mutation in chronic myeloproliferative disorders. Blood 106:2162\u20132168","journal-title":"Blood"},{"key":"3_CR30","doi-asserted-by":"publisher","first-page":"4187","DOI":"10.1182\/blood-2005-03-1287","volume":"105","author":"K. Kaushansky","year":"2005","unstructured":"Kaushansky K (2005) On the molecular origin of the chronic myeloproliferative disorders: it all makes sense. Blood 105:4187\u20134190","journal-title":"Blood"},{"key":"3_CR31","doi-asserted-by":"crossref","first-page":"189a","DOI":"10.1182\/blood.V104.11.189.189","volume":"104","author":"R.T. Silver","year":"2004","unstructured":"Silver RT, Fruchtman SM, Feldman EJ et al (2004) Imatinib mesylate (Gleevec) is effective in the treatment of polycythemia vera: a multi-institutional clinical trial. Blood 104:189a","journal-title":"Blood"},{"key":"3_CR32","doi-asserted-by":"publisher","first-page":"3339","DOI":"10.1182\/blood-2005-09-3917","volume":"107","author":"A.V. Jones","year":"2006","unstructured":"Jones AV, Silver RT, Waghorn K et al (2006) Minimal molecular response in polycythemia vera patients treated with imatinib or with interferon alpha. Blood 107:3339\u20133341","journal-title":"Blood"},{"key":"3_CR33","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1182\/blood-2006-03-009860","volume":"108","author":"J.J. Kiladjian","year":"2006","unstructured":"Kiladjian JJ, Cassinat B, Turlure P et al (2006) High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a. Blood 108:2037\u20132040","journal-title":"Blood"}],"container-title":["Internal and Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-007-0003-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11739-007-0003-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1007\/s11739-007-0003-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-007-0003-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T19:54:54Z","timestamp":1630439694000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11739-007-0003-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,3]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,3]]}},"alternative-id":["3"],"URL":"https:\/\/doi.org\/10.1007\/s11739-007-0003-4","relation":{},"ISSN":["1828-0447","1970-9366"],"issn-type":[{"value":"1828-0447","type":"print"},{"value":"1970-9366","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,3]]},"assertion":[{"value":"31 August 2006","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2006","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2007","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}